keyword
MENU ▼
Read by QxMD icon Read
search

Radioembolization

keyword
https://www.readbyqxmd.com/read/29786487/diffusion-weighted-mri-is-superior-to-pet-ct-in-predicting-survival-of-patients-undergoing-90-y-radioembolization-of-hepatic-metastases
#1
Alexandra Barabasch, Alexander Heinzel, Philipp Bruners, Nils A Kraemer, Christiane K Kuhl
Purpose To determine the relationship between diffusion-weighted (DW) liver MR images obtained 4-6 weeks after lobar yttrium 90 (90 Y) treatment and overall survival in comparison with PET/CT or established oncologic factors known to affect survival. Materials and Methods The institutional review board approved this prospective intraindividual comparative study in 36 consecutive patients (25 women) with liver-dominant metastases (20 colorectal, 14 breast, two other) (mean age, 60 years ± 10 [standard deviation]) who underwent fluorine 18 (18 F) fluorodeoxyglucose (FDG) PET/CT and DW MRI before and 4-6 weeks after 90 Y radioembolization...
May 21, 2018: Radiology
https://www.readbyqxmd.com/read/29766239/-90-y-resin-microspheres-radioembolization-for-colon-cancer-liver-metastases-using-full-strength-contrast-material
#2
I Kurilova, R G H Beets-Tan, G A Ulaner, F E Boas, E N Petre, H Yarmohammadi, E Ziv, A R Deipolyi, L A Brody, M Gonen, Constantinos T Sofocleous
OBJECTIVES: To assess safety and efficacy of 90 Y resin microspheres administration using undiluted non-ionic contrast material (UDCM) {100% Omnipaque-300 (Iohexol)} in both the "B" and "D" lines. MATERIALS AND METHODS: We reviewed all colorectal cancer liver metastases patients treated with 90 Y resin microspheres radioembolization (RAE) from 2009 to 2017. As of April 2013, two experienced operators started using UDCM (study group) instead of standard sandwich infusion (control group)...
May 15, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29755783/erratum-to-updated-survival-outcomes-and-analysis-of-long-term-survivors-from-the-more-study-on-safety-and-efficacy-of-radioembolization-in-patients-with-unresectable-colorectal-cancer-liver-metastases
#3
Andrew Kennedy, Michael Cohn, Douglas M Coldwell, Alain Drooz, Eduardo Ehrenwald, Adeel Kaiser, Charles W Nutting, Steven C Rose, Eric A Wang, Michael A Savin
[This corrects the article DOI: 10.21037/jgo.2017.03.10.].
April 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29755770/safety-and-initial-efficacy-of-radiation-segmentectomy-for-the-treatment-of-hepatic-metastases%C3%A2
#4
Craig Meiers, Amy Taylor, Brian Geller, Beau Toskich
Background: Hepatic metastatectomy and ablation are associated with prolonged survival, but not all lesions are anatomically amenable to these therapies. We evaluated safety and initial efficacy of segmental ablative transarterial radioembolization, or radiation segmentectomy (RS), as a treatment for hepatic metastases. Methods: A single institution retrospective analysis was performed of patients with hepatic metastases, determined unamenable to resection by a multidisciplinary tumor board, treated with RS from 2015-2017...
April 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29754852/predictors-of-survival-after-yttrium-90-radioembolization-for-colorectal-cancer-liver-metastases
#5
Ashley A Weiner, Bin Gui, Neil B Newman, John L Nosher, Fady Yousseff, Shou-En Lu, Gretchen M Foltz, Darren Carpizo, Jonathan Lowenthal, Darryl A Zuckerman, Ben Benson, Jeffrey R Olsen, Salma K Jabbour, Parag J Parikh
PURPOSE: To identify clinical parameters that are prognostic for improved overall survival (OS) after yttrium-90 radioembolization (RE) in patients with liver metastases from colorectal cancer (CRC). MATERIALS AND METHODS: A total of 131 patients who underwent RE for liver metastases from CRC, treated at 2 academic centers, were reviewed. Twenty-one baseline pretreatment clinical factors were analyzed in relation to OS by the Kaplan-Meier method along with log-rank tests and univariate and multivariate Cox regression analyses...
May 10, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29753675/patient-radiation-exposure-in-transradial-versus-transfemoral-yttrium-90-radioembolization-a-retrospective-propensity-score-matched-analysis
#6
Joshua Loewenstern, Colton Welch, Safet Lekperic, Vivian Bishay, Mona Ranade, Rahul S Patel, Edward Kim, F Scott Nowakowski, Robert A Lookstein, Aaron M Fischman
PURPOSE: To compare differences in patient radiation exposure (PRE) during transarterial yttrium-90 (90 Y) radioembolization (TARE) between transradial access (TRA) and transfemoral access (TFA). MATERIALS AND METHODS: A total of 810 consecutive first-time TARE procedures in patients from 2013 to 2017 were retrospectively reviewed. A propensity score-matching (PSM) analysis matched TRA and TFA groups on the basis of patient age, sex, weight, height, cancer type, 90 Y microsphere type, and number of previous procedures from the same and opposite approaches...
May 9, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29737954/-90-y-radioembolization-for-hepatic-malignancy-in-patients-with-previous-biliary-intervention-multicenter-analysis-of-hepatobiliary-infections
#7
Kavi K Devulapalli, Nicholas Fidelman, Michael C Soulen, Matthew Miller, Matthew S Johnson, Eric Addo, Ghassan El-Haddad, Charles Nutting, James Morrison, Khashayar Farsad, R Peter Lokken, Ron C Gaba, Jacob Fleming, Daniel B Brown, Sharon W Kwan, Steven C Rose, Kevin A Pennycooke, David M Liu, Sarah B White, Ripal Gandhi, Ann A Lazar, Robert K Kerlan
Purpose To determine the frequency of hepatobiliary infections after transarterial radioembolization (TARE) with yttrium 90 (90 Y) in patients with liver malignancy and a history of biliary intervention. Materials and Methods For this retrospective study, records of all consecutive patients with liver malignancy and history of biliary intervention treated with TARE at 14 centers between 2005 and 2015 were reviewed. Data regarding liver function, 90 Y dosimetry, antibiotic prophylaxis, and bowel preparation prophylaxis were collected...
May 8, 2018: Radiology
https://www.readbyqxmd.com/read/29724520/long-term-toxicity-after-transarterial-radioembolization-with-yttrium-90-using-resin-microspheres-for-neuroendocrine-tumor-liver-metastases
#8
Yuki Tomozawa, Younes Jahangiri, Priya Pathak, Kenneth J Kolbeck, Ryan C Schenning, John A Kaufman, Khashayar Farsad
PURPOSE: To evaluate long-term effects of yttrium-90 (90 Y) transarterial radioembolization (TARE) for unresectable hepatic metastases of neuroendocrine tumors (NETs). MATERIALS AND METHODS: Retrospective analysis of 93 patients (47 women, 46 men; mean age 59 y) who underwent resin-based 90 Y TARE was performed. Variables associated with overall survival were analyzed using univariate and multivariate models. Changes in serologic values and imaging characteristics were assessed with long-term follow-up...
April 30, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29724518/response-and-overall-survival-for-yttrium-90-radioembolization-of-hepatic-sarcoma-a-multicenter-retrospective-study
#9
Matthew D Miller, Daniel Y Sze, Siddharth A Padia, Robert J Lewandowski, Riad Salem, Philani Mpofu, Paul M Haste, Matthew S Johnson
PURPOSE: To evaluate the effectiveness and safety of yttrium-90 transarterial radioembolization (TARE) for the treatment of primary and metastatic soft tissue sarcoma (STS) of the liver. MATERIALS AND METHODS: A retrospective review of 39 patients with primary (n = 2) and metastatic (n = 37) hepatic STS treated with TARE at 4 institutions was performed. Fourteen STS subtypes were included, with leiomyosarcoma being the most common (51%). TARE with glass (22 patients) or resin (17 patients) microspheres was performed, with single lobe (17 patients) or bilobar treatment (22 patients) based on disease burden...
April 30, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29721125/contrast-enhanced-ultrasound-identifies-early-extrahepatic-collateral-contributing-to-residual-hepatocellular-tumor-viability-after-transarterial-chemoembolization
#10
Sriharsha Gummadi, Maria Stanczak, Andrej Lyshchik, Flemming Forsberg, Colette M Shaw, John R Eisenbrey
The mainstay of treatment for unresectable hepatocellular carcinoma is locoregional therapy including percutaneous ablation and transarterial chemo- and radioembolization. While monitoring for tumor response after transarterial chemoembolization is crucial, current imaging strategies are suboptimal. The standard of care is contrast-enhanced magnetic resonance imaging or computed tomography imaging performed at least 4 to 6 weeks after therapy. We present a case in which contrast-enhanced ultrasound identified a specific extra-hepatic collateral from the gastroduodenal artery supplying residual viable tumor and assisting with directed transarterial management...
June 2018: Radiology Case Reports
https://www.readbyqxmd.com/read/29721086/a-supramolecular-approach-for-liver-radioembolization
#11
Silvia J Spa, Mick M Welling, Matthias N van Oosterom, Daphne D D Rietbergen, Mark C Burgmans, Willem Verboom, Jurriaan Huskens, Tessa Buckle, Fijs W B van Leeuwen
Hepatic radioembolization therapies can suffer from discrepancies between diagnostic planning (scout-scan) and the therapeutic delivery itself, resulting in unwanted side-effects such as pulmonary shunting. We reasoned that a nanotechnology-based pre-targeting strategy could help overcome this shortcoming by directly linking pre-interventional diagnostics to the local delivery of therapy. Methods: The host-guest interaction between adamantane and cyclodextrin was employed in an in vivo pre-targeting set-up...
2018: Theranostics
https://www.readbyqxmd.com/read/29718791/radioembolization-in-advanced-hepatocellular-carcinoma
#12
Ahsun Riaz, Robert Lewandowski, Riad Salem
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
May 2, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29715141/liver-dominant-breast-cancer-metastasis-a-comparative-outcomes-study-of-chemoembolization-versus-radioembolization
#13
Jodie Chang, Resmi Charalel, Christopher Noda, Raja Ramaswamy, Seung Kwon Kim, Michael Darcy, Gretchen Foltz, Olaguoke Akinwande
AIM: To compare toxicity, response, and survival outcomes of patients with hepatic metastases from breast cancer who underwent transarterial chemoembolization (TACE) or radioembolization (TARE). MATERIALS AND METHODS: A retrospective review was carried out of all patients who underwent TACE or TARE for liver-dominant breast cancer metastases between January 2006 and March 2016 at an academic medical center in the United States. RESULTS: Seventeen patients in the TACE group and 30 patients in the TARE group received 32 TACE and 49 TARE treatments, respectively...
May 2018: Anticancer Research
https://www.readbyqxmd.com/read/29705239/re-validation-of-response-to-yttrium-90-radioembolization-for-hepatocellular-carcinoma-with-portal-vein-invasion
#14
Carlo Sposito, Carlo Spreafico, Vincenzo Mazzaferro
No abstract text is available yet for this article.
April 26, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29675774/radioembolization-for-hepatocellular-carcinoma-arising-in-the-setting-of-a-congenital-extrahepatic-portosystemic-shunt-abernethy-malformation
#15
Thomas Kroencke, Marcus Murnauer, Frank Alexander Jordan, Vera Blodow, Hannes Ruhnke, Tina Schaller, Bruno Märkl
In a 50-year-old male with an incidentally discovered hepatocellular carcinoma, a congenital extrahepatic portosystemic shunt with the absence of the portal vein (Abernethy syndrome) was diagnosed by imaging. This study aims to discuss the variant anatomy relevant to this splanchnic vascular malformation, review its association with the development of liver neoplasms, and report the safety and efficacy of TARE followed by resection for a HCC arising in this rare condition.
April 19, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29670363/long-term-survival-with-transarterial-chemoembolization-and-radioembolization-in-a-patient-with-cancers-of-unknown-primary
#16
Gokmen Aktas, Tulay Kus, Taylan Metin, Selim Kervancioglu, Umut Elboga
Cancers of unknown primary (CUP) are histologically proven metastatic malignant tumors without an identified primary site before treatment. The common characteristics are early dissemination, lower response to chemotherapy and poor prognosis with short life expectancy. Treatment was directed according to the presence of localized or disseminated disease. The most frequent site of metastasis is the liver, which is a suitable target organ for arterial-directed therapies. We report a case of 53-year-old woman who was diagnosed with CUP and suspected with intracellular cholangiocellular carcinoma (ICC), presented with a very large, unresectable, chemotherapy-refractory hepatic mass and treated with transarterial chemoembolization and transarterial radioembolization and surprisingly followed for 48 months with minimally progressive and stable disease...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29661994/baseline-apparent-diffusion-coefficient-as-a-predictor-of-response-to-liver-directed-therapies-in-hepatocellular-carcinoma
#17
Andrew Niekamp, Reham Abdel-Wahab, Joshua Kuban, Bruno C Odisio, Armeen Mahvash, Manal M Hassan, Aliya Qayyum, Ahmed Kaseb, Rahul A Sheth
Predicting outcomes in patients with hepatocellular carcinoma (HCC) who undergo locoregional therapies remains a substantial clinical challenge. The purpose of this study was to investigate pre-procedure diffusion weighted magnetic resonance imaging (DW-MRI) as an imaging biomarker for tumoral response to therapy for patients with HCC undergoing drug eluting embolic (DEE) chemoembolization and radioembolization. A retrospective review of HCC patients who underwent DEE chemoembolization or radioembolization was performed...
April 14, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29659390/combined-18f-fluoroethylcholine-pet-ct-and-99mtc-macroaggregated-albumin-spect-ct-predict-survival-in-patients-with-intermediate-stage-hepatocellular-carcinoma
#18
Markus Hartenbach, Stefan Weber, Magdalena Pilz, Sabrina Hartenbach, Mathias J Zacherl, Philipp M Paprottka, Reinhold Tiling, Peter Bartenstein, Marcus Hacker, Alexander R Haug, Nathalie L Albert
AIM: The aim of this study was to retrospectively analyze the prognostic value of combined Tc-macroaggregated albumin (MAA) SPECT/CT and [F]-fluoroethylcholine (FEC) PET/CT before radioembolization for survival of patients with intermediate-stage hepatocellular carcinoma. METHODS: Twenty-four patients with known hepatocellular carcinoma Barcelona Clinic Liver Cancer stage B were eligible for this analysis. All patients were scheduled for radioembolization and received a pretherapeutic [F]FEC PET/CT scan as well as Tc-MAA SPECT/CT for hepatopulmonary shunting...
April 13, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29651580/hepatotoxic-dose-thresholds-by-positron-emission-tomography-after-yttrium-90-radioembolization-of-liver-tumors-a-prospective-single-arm-observational-study
#19
Keith T Chan, Adam M Alessio, Guy E Johnson, Sandeep Vaidya, Sharon W Kwan, Wayne Monsky, Ann E Wilson, David H Lewis, Siddharth A Padia
PURPOSE: To define a threshold radiation dose to non-tumoral liver from 90 Y radioembolization that results in hepatic toxicity using pair-production PET. MATERIALS AND METHODS: This prospective single-arm study enrolled 35 patients undergoing radioembolization. A total of 34 patients (27 with HCC and 7 with liver metastases) were included in the final analysis. Of 27 patients with underlying cirrhosis, 22 and 5 patients were Child-Pugh A and B, respectively. Glass and resin microspheres were used in 32 (94%) and 2 (6%) patients, respectively...
April 12, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29644706/preparation-and-evaluation-of-188-re-sulfide-colloidal-nanoparticles-loaded-biodegradable-poly-l-lactic-acid-microspheres-for-radioembolization-therapy
#20
Mina Jamre, Mojtaba Shamsaei, Mostafa Erfani, Sodeh Sadjadi, Mohammad Ghannadi Maragheh
Radioembolization with radioactive microspheres has been an effective method for the treatment of liver lesions. The aim of this study was to prepare carrier-free 188 Re loaded poly (L-lactic acid) (PLLA) microspheres through 188 Re sulfide colloidal nanoparticles (188 Re-SC nanoparticles). The formation of 188 Re-SC nanoparticles was confirmed by ultraviolet-visible spectrophotometry. The labeling yield of 188 Re-SC nanoparticles was verified using the RTLC method. Effects of synthesis parameters on morphology and size of prepared 188 Re-sulfide colloidal-PLLA microspheres (188 Re-SC-PLLA microspheres) were studied by scanning electron microscopy...
April 12, 2018: Journal of Labelled Compounds & Radiopharmaceuticals
keyword
keyword
13605
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"